Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Gains Canadian Rights To Five Eye Assets From Harrow

While Two Assets Are Available, Three Are Due For Potential Approval

Executive Summary

Harrow has handed the licensing rights to Apotex for five of its ophthalmic assets in Canada that are in different phases of commercialization and development.

You may also be interested in...



Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend

M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.

Deal Watch: Biogen, AbCellera Team To Find Novel Way To Cross Blood-Brain Barrier

Plus deals involving BiomX/Adapative Phage, One/NEX-I, Shionogi/FunPep, Taiho/Haihe, Kinnate/Pierre Fabre, StemCell Technologies/SQZ and more, as well as tech transfer agreements.

Apotex, Heritage, Breckenridge US Price-Fixing Settlements Could Top $50m

Direct purchasers of drugs from a trio of generics manufacturers in the US say they will receive payments that are fair and reasonable, under settled agreements that have been put before a judge in Pennsylvania.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel